Fresenius Ventures MD: Europe's Investor Base Isn't the Problem

By Amara Osei

Europe's biotech funding gap comes down to capital, not investors. That's the verdict from Fresenius Ventures' managing director, speaking to European Biotechnology Magazine under the headline: "Europe has the investors. It needs the capital."

It's a blunt framing from inside one of Europe's most active corporate venture arms. Fresenius Ventures invests off the balance sheet of Fresenius, the German healthcare group, and its managing director sits squarely in the debate over why European biotech keeps lagging the US in company-building capital.

What does the claim actually mean?

The distinction matters. If Europe lacked investors — funds, family offices, corporates, institutional limited partners — the fix would be structural and slow. You'd have to build a venture ecosystem from scratch.

But the managing director's argument runs the other way. The investors exist. They're already in the market, already writing cheques, already doing due diligence. What's missing is the capital behind them, at the scale that US biotech takes for granted.

That puts the problem somewhere different: in the depth of funding pools, not in the number of firms or the quality of talent sourcing deals.

Why does the wording carry weight?

Fresenius Ventures speaks with the authority of a corporate investor that backs healthcare companies directly adjacent to its parent's core business. When its managing director says the constraint is capital supply, that's a signal to founders and policymakers alike.

For founders, the message is to plan financing rounds around a thinner late-stage market in Europe and to treat US investors as a likely necessity at scale.

For policymakers, it sharpens an old question. If the investor base is intact, then pension funds, sovereign wealth pools and other large allocators are the leverage point — the capital that isn't yet flowing into European life-science funds at volume.

What happens next?

Expect the capital-versus-investors framing to recur in European biotech policy debates, because it names a fixable problem. Money can move faster than ecosystems can be built, and the managing director's comments give ammunition to those pushing for deeper institutional commitment to the continent's life-science funds.